Biofrontera Q3 revenue rises 30% on higher Ameluz sales

By Reuters News


Overview

  • US biopharma firm's Q3 revenue rose 30% yr/yr to $9.1 mln

  • Company posted Q3 net loss of $6.4 mln, slightly improved from prior year

  • Q3 adjusted EBITDA loss narrowed to $5.5 mln from $6.0 mln last year


Outlook

  • Company preparing to commercialize Ameluz for sBCC in late Q4 2026 and early Q1 2027

  • Company submitted supplemental New Drug Application to expand Ameluz label for actinic keratosis


Result Drivers

  • AMELUZ UNIT VOLUME - Co said revenue growth was primarily due to a 23.3% increase in Ameluz unit volume, with additional contributions from price/mix and device sales

  • ACCELERATED CUSTOMER ORDERS - Co said part of the unit volume increase was driven by customers accelerating orders in anticipation of potential supply restrictions from the ITC exclusion order


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$9.1 mln

$8.50 mln (1 Analyst)

Q3 Loss Per Share

$0.42

Q3 Net Loss

$6.4 mln

Q3 Adjusted EBITDA

-$5.5 mln

-$1.40 mln (1 Analyst)


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Biofrontera Inc is $3.00, about 224% above its November 12 closing price of $0.93

  • The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 84 three months ago


Reuters Recommended Reads

  • Nov 12 - Verrica reports narrower-than-expected Q3 adjusted loss per share, YCANTH revenue grows

  • Nov 12 - Israeli dermatology firm Sol-Gel's Q3 net loss narrows on lower R&D expenses

  • Nov 12 - Journey Medical's Q3 revenue rises on Emrosi demand but misses estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.